tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2013-2-81-85tumors-37Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSРОЛЬ ПРЕПАРАТОВ ЖЕЛЕЗА В ЛЕЧЕНИИ АНЕМИИ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХThe role of iron supplements in the treatment of anemia in cancer patients.СнеговойА. В.SnegovoyA. V.ФГБУ РОНЦ им. Н. Н. Блохина РАМНRussian Federation201320052015028185Copyright © Снеговой А.В., 20152015Снеговой А.В.Snegovoy A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/37

Проблема анемии у онкологических больных является актуальной и многогранной. Одной из причин развития анемии является дефицит железа. Абсолютная или функциональная нехватка железа снижает эффективность применения рекомбинантного эритропоэтина, используемого для лечения анемии индуцированной химиотерапией. Многочисленные исследования показали, что внутривенные формы железа, в отличие от пероральных, эффективно восполняют дефицит железа необходимый для оптимального эритропоэза. Современные американские и европейские рекомендации (ESMO, NCCN) по лечению анемии у онкологических больных включают обязательное использование внутривенных форм железа.

The problem of anemia in cancer patients is relevant and multilateral. One of the causes of anemia is iron deficiency. The absolute or functional iron deficiency reduces the efficiency of recombinant erythropoietin used for the treatment of chemotherapy-induced anemia. Numerous studies have shown that intravenous forms of iron, as opposed to oral, effectively replenish iron deficiency necessary for optimal erythropoiesis. Modern American and European recommendations (ESMO, NCCN) for the treatment of anemia in cancer patients include the mandatory use of intravenous forms of iron.

анемияхимиотерапияжелезодефицитная анемияэритропоэзanemiachemotherapyiron-deficiency anemiaerythropoiesisReferencesLudwig H, Van Bells S, Barret-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-306.Ludwig H, Van Bells S, Barret-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-306.Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.Khorana A, Francis C, Blumberg N, et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81.Khorana A, Francis C, Blumberg N, et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-81.Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: update meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-14.Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: update meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-14.Абрамов М. Е. Анемия на фоне химиотерапии. Пути коррекции. Фарматека 2012;№ 8:50-54.Абрамов М. Е. Анемия на фоне химиотерапии. Пути коррекции. Фарматека 2012;№ 8:50-54.Птушкин В. В. Анемия в онкологии: подходы к лечению. Современная онкология 2012; т.14;№ 1:58-63.Птушкин В. В. Анемия в онкологии: подходы к лечению. Современная онкология 2012; т.14;№ 1:58-63.Aapro M, Osterborg A, Gasco P. et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v.iron. Ann. Oncol.2012.doi:10.1093 / annonc / mds112.Aapro M, Osterborg A, Gasco P. et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v.iron. Ann. Oncol.2012.doi:10.1093 / annonc / mds112.Павлов А. Д., Морщакова Е. Ф., Румянцева А. Г. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантными человеческим эритропоэтином. Современная онкология 2002;№ 4:50-54.Павлов А. Д., Морщакова Е. Ф., Румянцева А. Г. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантными человеческим эритропоэтином. Современная онкология 2002;№ 4:50-54.D hrsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67 (2): 235-9.D hrsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67 (2): 235-9.De Rienzo DP, Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990; 86: 80-3.De Rienzo DP, Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990; 86: 80-3.Krause A, Neitz S, Magert H et al. LEAP-1, a novel highly disulde-bonded human peptide, exhibits antimicrobial activity. FEBS Letters 480 (2000) 147-150.Krause A, Neitz S, Magert H et al. LEAP-1, a novel highly disulde-bonded human peptide, exhibits antimicrobial activity. FEBS Letters 480 (2000) 147-150.Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-10.Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-10.Милованов Ю. С., Милованова Л. Ю., Козловская Л. В. Нефрогенная анемия: патогенез, прогностическое значение, принципы лечения. Клиническая нефрология. 2010;6:7-18.Милованов Ю. С., Милованова Л. Ю., Козловская Л. В. Нефрогенная анемия: патогенез, прогностическое значение, принципы лечения. Клиническая нефрология. 2010;6:7-18.Дворецкий Л. И. Железодефицитная анемия в практике терапевта. Русский медицинский журнал. 2009;23:1517-21.Дворецкий Л. И. Железодефицитная анемия в практике терапевта. Русский медицинский журнал. 2009;23:1517-21.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer- and chemotherapy-induced Anemia. Version 2.2012 (R). www.NCCN.org.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer- and chemotherapy-induced Anemia. Version 2.2012 (R). www.NCCN.org.Crichton R, Danielson G, Geisser P. Iron therapy with special emphasis on intravenous administration. Science 2008, 1-127.Crichton R, Danielson G, Geisser P. Iron therapy with special emphasis on intravenous administration. Science 2008, 1-127.Auerbach M, Ballard H, Trout R et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin.Oncol. 2004;22:1301-7.Auerbach M, Ballard H, Trout R et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin.Oncol. 2004;22:1301-7.Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-8.Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-8.Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy- related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008; 26: 1619-25.Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy- related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008; 26: 1619-25.Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116 (3):522-25.Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010;116 (3):522-25.Steinmetz T, Tschechne B, Virgin G. Ferric Carboxymaltose for the Correction of Cancer- and Chemotherapy-Induced Anaemia in Clinical Practice. J. Support Cancer Care 2010;19:261.Steinmetz T, Tschechne B, Virgin G. Ferric Carboxymaltose for the Correction of Cancer- and Chemotherapy-Induced Anaemia in Clinical Practice. J. Support Cancer Care 2010;19:261.D. Schrijvers, H. De Samblanx, F. Roila. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology 21 (Supplement 5): v244 — v247, 2010D. Schrijvers, H. De Samblanx, F. Roila. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology 21 (Supplement 5): v244 — v247, 2010doi:10.1093 / annonc / mdq202.doi:10.1093 / annonc / mdq202.

The authors declare that there are no conflicts of interest present.